The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Recommended phase (Ph) II dose (RP2D) selection for investigational Aurora A kinase (AAK) inhibitor MLN8237 (Alisertib; A) combined with paclitaxel (P): Clinical pharmacokinetics (PK), drug-drug interaction (DDI) assessment, and translational exposure-efficacy modeling.
Karthik Venkatakrishnan
Employment or Leadership Position - Millennium
Xiaofei Zhou
Employment or Leadership Position - Millennium
Jeffrey Ecsedy
Employment or Leadership Position - Millennium
Jerome Mettetal
Employment or Leadership Position - Millennium
Ely Benaim
Employment or Leadership Position - Millennium
Stock Ownership - Millennium
Hua Liu
Employment or Leadership Position - Millennium
Gerald Steven Falchook
Research Funding - Millennium
Howard Fingert
Employment or Leadership Position - Millennium
Wen Chyi Shyu
Employment or Leadership Position - Millennium
Robert Kleinfield
Employment or Leadership Position - Millennium
Ashley Milton
Employment or Leadership Position - Millennium